Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276936 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
A Phase 3 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
NCT03276936 is a Phase 3 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 504 participants.
The verdict
NCT03276936, a Phase 3 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
Study Summary
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
Interventions
- DRUG FMX103 1.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2019-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03276936
The ClinicalTrials.gov registry entry for NCT03276936 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FMX103 1.5% is the first listed.
NCT03276936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03276936 about?
NCT03276936 is a clinical study titled "A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea". The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
What is the current status of trial NCT03276936?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2017-09-05. Estimated completion is 2019-01-15.
What interventions are being tested in trial NCT03276936?
The interventions under investigation include: FMX103 1.5% (DRUG).
Who is sponsoring clinical trial NCT03276936?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.